Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • AAP Policy
    • Topic/Program Collections
    • Policy
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effect on Pediatric Health
    • More Collections...
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Alerts
    • Table of Contents
    • Insights
  • AAP Career Center
  • Subscribe
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • AAP Policy
    • Topic/Program Collections
    • Policy
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effect on Pediatric Health
    • More Collections...
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Alerts
    • Table of Contents
    • Insights
  • AAP Career Center
  • Subscribe

Pfizer, BioNTech report COVID-19 vaccine safe, highly effective in 12- to 15-year-olds

Melissa Jenco, News Content Editor
March 31, 2021

Editor’s note:For the latest news on COVID-19, visit http://bit.ly/AAPNewsCOVID19.

Pfizer-BioNTech’s COVID-19 vaccine was safe and 100% effective in protecting adolescents ages 12-15 in a phase 3 trial, the companies said Wednesday.

Trial data have not been validated by U.S. health officials, but the companies said they plan to submit them to the Food and Drug Administration (FDA) in the coming weeks so that adolescents can start to be vaccinated.

“It is very important to enable them to get back to everyday school life and to meet friends and family while protecting them and their loved ones,” BioNTech CEO and co-founder Ugur Sahin, M.D., said in a news release.

About 2,260 adolescents ages 12-15 years participated in the trial, with roughly half receiving the vaccine and half receiving a placebo. There were 18 cases of COVID-19 reported, all within the placebo group. One month after a second dose, the vaccine elicited SARS-CoV-2-neutralizing antibody geometric mean titers of 1,239.5 in a subset of adolescents, compared to 705.1 in an earlier group of 16- to 25-year-olds, according to the news release.

The companies said side effects were consistent with those seen in older teens and young adults. Since December, the vaccine has been used for people ages 16 and older under emergency use authorization from the FDA.

Pfizer and BioNTech recently began to study their vaccine in children ages 6 months through 11 years. Children as young as 5 have received the vaccine in that trial, and testing will begin in those as young as 2 next week.

Moderna also has been testing its COVID-19 vaccine in children with trials in 12- to 17-year-olds. In mid-March, it announced it was starting a trial in children ages 6 months through 11 years.

The AAP has continued to push for pediatric vaccine trials as children and adolescents make up about 13.4% of cases. More than 3.4 million children have been infected with SARS-CoV-2 and at least 279 have died, according to data from the AAP and the Children’s Hospital Association. The pandemic also has taken a toll on children’s mental and emotional health, social well-being and their educational experience.

Resources
  • CDC guidance for clinicians on each of the three authorized COVID-19 vaccines
  • AAP FAQs on COVID-19 vaccines
  • AAP interim guidance on COVID-19
Copyright © 2021 American Academy of Pediatrics

Advertising Disclaimer »

Download PDF
Email News Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pfizer, BioNTech report COVID-19 vaccine safe, highly effective in 12- to 15-year-olds
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Pfizer, BioNTech report COVID-19 vaccine safe, highly effective in 12- to 15-year-olds
Melissa Jenco
March 31, 2021
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Digital Edition Current Issue
  • Latest Daily News
  • Archives
  • Collections
  • Columns
  • Advertising
  • Subscribe to AAP News Magazine
  • Terms of Use
  • Privacy Statement
  • FAQ
  • Contact Us
  • 2021 AAP Journals Catalog
  • Pediatrics
  • Pediatrics in Review
  • Hospital Pediatrics
  • NeoReviews
  • AAP Grand Rounds
  • AAP Career Center
  • shopAAP
  • AAP.org
  • AAP News
  • Visit AAP News on Facebook
  • Follow AAP News on Twitter
American Academy of Pediatrics

© 2021 American Academy of Pediatrics